Return to Office Plan - BIP Capital

BIP Capital | Return-to-Office Plan Page 1 of 47

Return to Office Plan RETURN-TO-OFFICE PLAN


We are sharing our re-opening plan in the hope that it will prove a helpful resource to businesses working to design and implement their own re-opening plans during the ongoing 2020 pandemic. We do not purport to be experts. We are not attorneys. We are sharing these materials as guidance and we are not providing any legal, safety, or medical advice. Specifically, businesses working through re-opening plans should contact their own legal counsel to obtain, among other things, advice regarding applicable state and federal labor, employment, privacy, health, contract and/or real estate law. We are not healthcare providers and fully acknowledge that scientific understanding about the novel coronavirus and COVID-19 continues to evolve daily, such that the information contained herein may become stale or outdated. The most current source for information regarding federal, state and local guidelines, including guidance issued by the CDC and health departments, as well as OSHA and Labor Department regulations, and HIPPA and other privacy-related requirements are available online through the relevant enforcement agency’s website.

This is provided for informational purposes only and should not be relied upon for any other purpose. Certain aspects of the plan are unique to our company’s business and operations. Each plan will necessarily be tailored to the unique aspects of the implementing business, and will most likely require regular updating and enhancements over time. Before implementing a plan, we encourage you to contact your own legal advisor.

Effective Date: 05-26-20

Last Updated: 05-13-20

First Version: Plan Published


Table of Contents Letter from the CEO .................................................................................................4 Ecosystem Overview .................................................................................................6

Perspective 7 The BIP Ecosystem 8 Our Extended Ecosystem 9 Points of Contact 10 History as a Teacher 11

Plan Overview ...............................................................................................12

Goals & Objectives 13 Benefit of Our Plan 13 Phases ..........................................................................................................14

Phase 1-Restricted Access 14 Phase 2-Moderate Access 14 Phase 3-Least Restrictive 14

Protocols ..........................................................................................................16 Communication 16 Controlled Office Entry 16 Baseline Testing/Questionnaire 17 Ongoing Testing 18 Data Capture/Reporting 18 Contact Tracing 18 Health Information Security 18 General Building Sanitation 19 Office Sanitation 19 Employee Expectations 19 Employee Meeting Guidelines 20 Client & Port Co. Meeting Guidelines 20 Common Area Guidelines 20 Knowledge Sharing 21

Questionnaires ...............................................................................................22

Questionnaire 1: Baseline 23 Questionnaire 2: Symptoms 35

Appendix ...............................................................................................38

What We Know 39 General Facts Facts About COVID-19 Risk & Mitigation Factors

FAQs 45 About our Testing Protocols Limitations

46 47


Letter from the CEO

Team, I am writing to provide details of BIP Capital’s Return-to-Office Plan (the “Plan”), which has been developed in response to the pandemic resulting from the emergence of the novel coronavirus (a.k.a., SARS-CoV-2) and the disease it causes, COVID-19. As companies across the country struggle to figure out how best to return to their offices safely, I am calling on the entire team to do what we do so well – manage risk and solve problems. We built BIP Capital (the “Company”) on our ability to:

• assess and manage risks; • develop practical and effective solutions; • execute, • share and be open and, most importantly, • treat others ethically.

These pillars will serve us well as we work together to mitigate the risks associated with the pandemic. Plan Overview Our Plan has the following goals:

1) Establish return-to-office parameters for the safety of our employees, investors, entrepreneurial partners and their family members;

2) Develop a series of protocols aimed at reducing the risk of spreading coronavirus within our ecosystem; 3) Share our Plan framework with our portfolio companies for adaptation to their circumstances and ecosystems; 4) Establish and maintain an understanding of our company’s exposure to coronavirus; and 5) Share useful information developed as a result of the foregoing with the communities we inhabit, including the

broader business community and appropriate government offices. Phases Our Plan will have three Phases:

• Phase 1 – highly restricted office access with an opportunity for voluntary return for employees (telework will still be preferred and encouraged during this phase)

• Phase 2 – moderately restricted office access with voluntary return for employees (telework will still be available, and in many cases still preferred and encouraged during this phase)

• Phase 3 – less restrictive operations (this phase may only be entered when there is significantly reduced risk of disease contraction, and may still include telework)

Phase 1 will begin on May 26, 2020. Employees are strongly encouraged to continue to work remotely. Those insisting upon returning to the office will be required to take a serological blood test. We will utilize each employee’s results of the blood test to determine the employee’s likelihood of spreading the novel coronavirus and when/whether they will be permitted to return to our offices. These procedures will be repeated at least weekly for all of Phase 1 and 2. (Further details are contained in the Plan.) Phase 2 will begin when case levels in the state of Georgia and nationally are on a sustained downward trend (as determined by management), and in accordance with guidance issued by the federal government through the CDC and by the State.


Phase 3 will begin when management determines that there is a significantly reduced risk of disease contraction (may or may not include the availability of a vaccine). It is expected that all Phase-specific restrictions will cease when a vaccine or cure for COVID-19 has been developed and is readily accessible. Protocols We will use a series of protocols as the foundation for our Plan. These protocols are intended to mitigate specific risks believed to increase the likelihood that someone in our ecosystem contracts or spreads the virus as a result of in-person, business-related interactions. Detailed protocols address the following areas:

1) Establishing a Clear Communication Process for Phase 1 2) Controlled Office Entry in Phase 1 and 2 3) Baseline Testing & Questionnaire (Voluntary) 4) Ongoing Testing (Voluntary) 5) Data Capture/Reporting 6) Impact of a Positive Test on Group 7) Privacy and Health Information Security 8) General Building Sanitation 9) Office Sanitation 10) Employee Expectations 11) Guidelines for In-Person Meetings amongst Employees 12) Guidelines for In-Person Meetings with Clients & Entrepreneurs 13) Guidelines for Activities in Common Areas of the Office 14) Knowledge Sharing

Your Review of this Plan Please read this Plan thoroughly, with the same critical eye that you use to assess potential investments or internal business processes. Our ecosystem will look for us to provide thought-leadership and guidance on this subject. The plan we produce – and share – will be a direct reflection on our brand. It will reflect on our commitment to our partners and clients, and on how well we manage risk and solve problems. I welcome your specific, concise, constructive feedback (both positive and negative). It’s important that we build the best Return-to-Office Plan possible. This may be an iterative process as the facts and understanding relating to the pandemic continues to evolve and change daily. In Closing Our team’s early response to this crisis has been excellent, but we have remaining work to do. Please take the next step and help me design and implement a best-in-class Return-to-Office Plan. Thank you for all you do. Sincerely,

Mark A. Buffington

Mark A. Buffington, CEO


Return to Office Plan PART 1: ECOSYSTEM OVERVIEW


Perspective

In reading this Plan, consider the following points:

• This disease is serious. It’s significantly more serious than the flu. o Based on current CDC modeling (which is hampered by selection bias due to limited testing) COVID-

19’s Case Fatality Rate (CFR) is 0.5-2.5%. o In other words, 5-25 people in 1,000 who contract the disease die. o That is 5-25 times higher than the typical flu. o Unlike the typical flu: COVID-19 has a longer incubation period (up to 14 days), during which time the

infected person may not have any symptoms but is highly contagious.

• It would be easy to look at the Case Fatality Rate for COVID-19 and conclude that it is mostly safe to return to the office; but, as professional risk managers, we believe that logic is flawed. Like any statistic, this data requires thoughtful consideration and interpretation before it can form the basis of a conclusion:

o The ensemble risk (reflected in the .5-2.5% range) should be viewed in light of the potential outcomes, namely that a person (i.e., a loved one, client or business partner) could die after contracting the disease as a result of coming to our office. As described below, our ecosystem includes tens of thousands of people, some of whom are considered particularly vulnerable to severe, negative outcomes from COVID-19.

• For several weeks now we have conducted our business activities remotely, and in doing we have found that: o We have been able to deliver the same quality advice and substantially similar updates to investor clients

and our portfolio companies over digital meeting platforms as before the pandemic. o We have been able to find and vet investments with the same acumen that we did pre-pandemic. o We have been able to make more progress on big, strategic projects, as we have not been subject to

as many day-to-day distractions that are common in the office.

• On the other hand, without consistent in-person interaction, we have found it more difficult to: o raise capital from investors at the same pace, and o sustain the same corporate culture.

• Unlike many businesses, we are fortunate in that we have been able to maintain our value proposition to clients

despite working remotely. Accordingly, we do not have to aggressively open our offices in order to sustain operations or meet client responsibilities.

• As a result of the foregoing, we will be taking a cautious approach to reopening our offices in an effort to avoid, to the extent reasonably possible, the risk of spreading coronavirus within our ecosystem.

• We have built a lot together, and we want to continue building without inadvertently harming one or more of the

employees, clients, founders or portfolio company team members who are counting on us to provide real leadership in this time of chaos.


The BIP Ecosystem Our immediate ecosystem is defined as the people we are in contact with on a frequent basis through our work activities. Across BIP Capital & BIP Wealth, this includes employees and clients, as well as personnel at our portfolio companies and vendors. In total, there are about 3,100 people:

We have 39 employees at BIP Capital and BIP Wealth combined, and some of us are – according to current understanding of coronavirus –at higher risk for severe illness or death from COVID-19 because of age or underlying medical conditions (e.g., lung disease, asthma, hypertension, heart conditions, weakened immunity, diabetes, liver or kidney disease). BIP Capital and BIP Wealth serve over 1,200 households. Approximately 1/3 of BIP’s clients are over the age of 60, and approximately half are over the age of 50. We do not have a reliable estimate of chronic disease in our client base, but we know it is prevalent, just as it would be with any older population. BIP Capital is currently backing the startups of 36 founders. Our portfolio companies have over 2,000 employees, contractors, and franchisees. We have approximately 55 vendors and contractors that we work with on a frequent basis. We know that each of these constituencies also includes vulnerable persons.

39 BIP Employees

1,200+ Households

36 Company Founders

2,000+ Port. Co. Team Members

50+ Vendors


Our Extended Ecosystem Our extended ecosystem includes the families of our employees, clients, founders, portfolio company associates and vendors, as well as our buildings’ co-inhabitants, families and contacts.

The 39 BIP employees in our offices have:

• A combined family nucleus of ~ 145 • An extended family of ~ 350 • ~ 20% of our employees’ family nuclei are children • ~ 25% of our employees’ family nuclei are over the age of 50

BIP Capital and BIP Wealth combined advise over 1,200 households that have:

• An estimated immediate family in their homes that totals ~ 3,800 people (skews Boomer & “empty-nester”) • An estimated extended family that totals ~ 14,000 people

BIP Capital is currently backing the startups of 36 founders that have:

• Immediate family living in their homes that totals ~136 people (skews Gen X working age with children) • Extended family that totals ~320 people

Our portfolio companies have over 2,000 employees, contractors, and franchisees that have:

• An estimated immediate family living in their homes that totals ~ 5,800 people • An estimated extended family of ~17,400 people

We have approximately 55 vendors and contractors that we work with on a frequent basis.

• An estimated immediate family living in their homes that totals ~ 175 people • An estimated extended family of ~500 people

There are over 900 co-inhabitants in the two main office buildings (Buckhead & Alpharetta) where BIP Capital & BIP Wealth lease space.

• We do not have reliable estimates of the demographics of their respective families and contacts.

Employees - 39 people

BIP Ecosystem - ~ 3,000 people

Extended Ecosystem -~45,000 people


Points of Contact The members of our ecosystem cross paths frequently. Below is an estimate of the amount of traffic we experience at different facilities and events. Each of these visits and interactions represent an opportunity for members of our ecosystem to transmit diseases amongst one another.

• On normal business days we have: o 39 employees in our offices o 3-7 investors visit our offices o 2-5 founders visit our offices o 5-25 portfolio company team members visit our offices o 2-8 vendors enter our office

• On days we host presentations we experience an increase over normal business days:

o 5-75 additional investors (prospective and existing) attend o 1-4 additional vendors enter our office to provide lunch and other supplies

• At the BIP Capital Symposium we have:

o 350-450 investors attend o 40-70 portfolio company team members attend o 50+ catering staff attend o 10-20 other vendors attend

• At the BIP Capital Annual Shareholder Meeting we have:

o 200-300 investors attend o 39 BIP Employees attend o 40+ catering staff attend o 10-20 other vendors attend

• There are over 900 co-inhabitants of our office buildings with whom our employees, clients, founders and

portfolio company team members cross paths with in common areas, such as elevators, stairwells, bathrooms and lobbies.

• We attend networking events (conventions, conferences, startup showcases, panels, presentations, mixers, etc.)

as part of our normal business activities. o Most of these events are local (~80%) o But some require travel (which means airline travel, hotel stays, prolonged stagnant periods in confined

spaces) Our goal is to control the risks we can control and to follow the CDC and OSHA’s guidelines for reducing workplace exposure for everyone in our ecosystem.


History as a Teacher This is not the first pandemic. We have important historical context to understand different approaches to dealing with pandemics and the differences in outcomes (measured in terms of fatalities) of “flattening the curve” vs. allowing natural processes to run their course unfettered. A Tale of Two Cities – The Spanish Flu (Spring 1918-Summer 1919) Philadelphia did not limit social interaction – they even promoted it with a parade – and they saw a rapid spike and then decline in deaths. After a rapid rise in illnesses, the Philadelphia community developed herd immunity and new cases subsided quickly (because the majority of the population had been infected already and had antibodies that provided immunity from subsequent infection). Notwithstanding the foregoing, the economy in Philadelphia took years to recover due to the relatively brief but catastrophic disruption caused by the disease and deaths. In stark contrast, St. Louis began aggressively implementing social distancing guidelines and quarantining just days after the first reported cases. They waited months before they returned to work and more normal social activities. During that time, St. Louis had far fewer deaths, but the pandemic extended over a much longer time. They also saw a second wave of outbreak that caused more deaths, but nowhere near what Philadelphia experienced by allowing natural forces to run their course. Ultimately, St. Louis’ economy was not hurt as badly as a result of the pandemic as compared to Philadelphia. The US Approach to Coronavirus Approximates the St. Louis Approach to Spanish Flu In the US, we have responded to the pandemic through interventions similar to those implemented in St. Louis. State and national governments have issued shelter-in-place orders, promoted social distancing, good personal hygiene, and the use of disinfectants, in an effort to slow the spread and to preserve the capacity of hospitals to treat severe cases. As we begin to return to workplaces and re-open our economies, it is likely that we will see additional waves of the outbreak (like St. Louis experienced with the Spanish Flu and their reopening). We must factor in this strong possibility when establishing the Plan. Recent History shows that Severe Flu & Coronavirus Outbreaks are on the Rise The current pandemic won’t be the last; many believe that global conditions are ripe for more frequent and severe outbreaks of disease. Indeed, recent global history has shown that the world is experiencing some form of dangerous disease outbreak every 4-6 years. As a society and a company, we need to build the muscles to deal with outbreaks in the future as they are likely to happen again in the near term. This is one of the guiding principles behind our Plan.


Return to Office Plan PART 2: PLAN OVERVIEW


Goals & Objectives With our Return-to-Office Plan we aim to create:

1. An on-site work environment that is as safe as practicable.

2. Enhancements to our work-from-home strategy that assists and improves employees’ ability to continue delivering value to investors and entrepreneurs remotely.

3. A combined work-from-home and return-to-office strategy that enables our employees to effectively raise new funds from new investors.

4. A foundation to prepare for future pandemics/infectious disease outbreaks.

Intended Benefits of Our Plan

1. Allows our employees to come back to the office if they want to when state and local Shelter-in-Place orders are fully lifted;

2. Attempts to identify employees who:

a. have already contracted and, as a result, have developed some immunity1 to the coronavirus;

b. have not previously contracted the coronavirus and, therefore, are currently healthy but still at-risk; or

c. are currently fighting the disease.

3. Increases the odds that we have a safe workplace;

4. Reduces the odds that our employees will contract the coronavirus as a result of returning to the office;

5. Reduces the odds that our clients and vendors will contract the coronavirus as a result of their inclusion in our ecosystem;

6. Provides process for obtaining informed consent from our employees, clients, founders, vendors and any other visitors or guests regarding the risks associated with entering our offices and/or having in-person contact during a pandemic.

7. Complies with federal, state and local guidelines for re-opening including, but not limited to, those issued by the CDC and OSHA;

8. Partners with health professionals, where necessary and/or appropriate, to assist us in our goals;

9. Sets clear in-office guidelines for interaction in common areas and meeting rooms;

10. Sets clear guidelines for use of masks or other personal protective equipment, good hygiene, and disinfectants; and

11. Establishes data reporting standards that protect employee’s rights, including their privacy, while also allowing us to contribute much needed, de-identified data to the community, including to healthcare policymakers.

1 Scientists are still researching the level of immunity infected individuals develop, particularly as they continue to monitor potential mutations of the coronavirus.


Phases Our Return-to-Office Plan will be divided into three phases that track federal guidelines for re-opening. Until new cases in Georgia are consistently declining (as determined by management), we will:

a. limit visits to our office and mandate compliance with protocols governing office entry; b. host events remotely; c. eliminate in-person attendance of networking events and any other non-essential business travel; and d. ask our employees to limit non-essential personal travel.

Phase 1: Limited Office Re-Opening

• Voluntary return to office with admission contingent on testing results, repeated at least weekly; • Mandatory compliance with in-office social distancing policy; • Staggered schedule with office operating at no more than 50 percent capacity, with employees in the

office no more than two days per week; • Vulnerable employees (including those who are over 65 and/or who have an underlying health

condition) are asked and strenuously encouraged to continue to shelter-in-place. Upon request, accommodations to roles and responsibilities will be made to ensure vulnerable employees can continue to exclusively work remotely;

• Office and business meetings available via Zoom to accommodate employees working from home; • No in-office client meetings; • Communal spaces closed, communal food sources prohibited; • Signage prominently displayed to promote healthy hygiene practices; • Enhanced cleaning, disinfection and ventilation (consistent with CDC guidelines); • No vendors in the office; • Data gathering through questionnaires and testing; • Employees returning to office avoid public transit and abstain from non-essential personal travel; and • Non-essential business travel prohibited.

Phase 2: Expanded Office Re-Opening (when cases are consistently declining in Georgia)

• Voluntary return to office with admission contingent on testing results, repeated at least weekly; • Mandatory compliance with in-office social distancing policy; • Continue to support and encourage vulnerable employees to work remotely; • Office and business meetings available via Zoom to accommodate employees working from home; • Select in-person client meetings allowed, contingent upon provision of informed-consent notification to

visitors and compliance with procedures for Phase 2 in-person meetings, including pre-approval from management;

• Signage prominently displayed to promote healthy hygiene practices; • Enhanced cleaning, disinfection and ventilation (consistent with CDC guidelines); • No vendors in the office; • Employees returning to office avoid public transit and abstain from non-essential personal travel; and • Business travel permitted, with prior approval from management, and in accordance with state and local

regulations and guidelines.

Note: Management will amend parameters of Phase 2 upon regular assessment of macro analysis of virus data and trends, within our community and within ecosystem;

Phase 3: Full Office Re-Opening (when there is significantly reduced risk of disease contraction)

• Return to office, with exceptions available for self-identified vulnerable employees or employees with self-identified vulnerable family members;


• Relaxed social distancing policies; • Signage prominently displayed to promote healthy hygiene practices; • Enhanced cleaning, disinfection and ventilation (consistent with CDC guidelines); • Pre-scheduled meetings available via Zoom to accommodate employees working from home; • Office fully re-opened to client meetings; contingent upon provision of informed-consent notification to

visitors and in compliance with procedures for Phase 3 in-person meetings; and • Limited access to office by vendors and other visitors, contingent upon provision of informed-consent

notification.

Note: Management will amend parameters of Phase 3 upon regular assessment of macro analysis of virus data and trends, within community and within ecosystem.


Protocols

Protocol 1: Establishing Clear Communication Process for Phase 1

Delivering the Plan This Plan will be reviewed at our weekly virtual staff meetings the week prior to commencement of Phase 1, with follow-on distribution to all employees by email. Each employee must sign an acknowledgement to document that he or she: (1) has reviewed; (2) understands; and (3) will comply with the Plan. Status Updates and Ongoing Communications The Company’s COO will be the primary point of contact as it relates to questions, coordination and/or implementation regarding the Plan. During Phase 1, 15-minute Return-to-Office updates will be conducted daily (Mon-Thurs) at 8:30am via Zoom webinar. Mandatory participants include:

• Management Team • Wellview Health Senior Point of Contact • All employees who have returned or are seeking to return to the office.

The purpose of the daily update is to identify and promptly address problems that may jeopardize a successful Return-to-Office program; direct changes to the Plan as warranted; and ensure timely dissemination of information to decision makers. Updates will move to a lower frequency based upon management’s assessment of a successful implementation of Phase 1.

Protocol 2: Controlled Office Entry for Phases 1 and 2

Staggered Schedules The Company will employ staggered schedules (Monday/Tuesday for Group A, Wednesday/Thursday for Group B, and Remote Fridays) for employees during Phase 1 to further mitigate the risk. Employees will be assigned to Groups by the COO with a view towards reducing workstation proximity and ensuring continuity of key business functions across teams. Groupings and staggered scheduling will be reviewed and potentially modified before implementing Phase 2. Vendor Management

i. Vendors will be required to remain outside the entrance area, near the elevator lobby. A sign with instructions and contact information will direct vendors to drop packages at the door or to contact a designated employee to sign for packages if necessary.

ii. When a visitor (vendor or otherwise) enters the Company’s office space, the visitor will be required to wear a protective mask/cloth face covering, will be shown the informed-consent notification (which may posted), and will be escorted for the entirety of their visit by an employee who will also wear a protective mask/cloth face covering and who will disinfect touch points upon the conclusion of the visit.


iii. Guests (i.e., clients, investors, portfolio company employees, etc.) will not be permitted in our offices until Phase 2 of this Plan.

Protocol 3: Baseline Testing & Questionnaire

Voluntary Baseline Testing Employees who voluntarily return to the office must agree to COVID-19 antibody testing, which will be paid for by the Company. Returning employees will be divided into two groups for in-office activities, with Group A returning to the office Monday-Tuesday and Group B returning to the office Wednesday-Thursday. Testing will be performed on Monday (for Group A employees) and Wednesday (for Group B employees) by clinicians from Wellview Health. Weekly voluntary testing is a prerequisite to return to the office during Phase 1 and Phase 2. Return-to-Office Baseline Questionnaire

i. Management will request that employees complete an electronic questionnaire to provide a baseline. Completion of the questionnaire is voluntary for all employees. Note: As stated above, completion of the baseline questionnaire is completely voluntary. Employees will not be subjected to any employment-related discipline for declining to complete the form or declining to authorize us to disclose the information contained on the form. No information submitted by an employee will be used in making an employment decision. By completing a questionnaire, however, employees agree that we may share the information in a de-identified and anonymous basis with third-parties, including the government.

Return-to-Office Testing Protocol

i. There will be one testing station located in the NW corner of the office in Buckhead (not the main entrance), operating from 7:00am to 10:00am on Mondays and Wednesdays; tests will be scheduled at 10-minute intervals.

ii. Testing will be administered by a Wellview Health clinician. If more than one employee is awaiting testing, employees will queue in the hallway on floor markings that ensure safe social distancing.

iii. Test results normally take less than 8 minutes and will be communicated to the employee immediately and confidentially by the Wellview Health clinician. Test results will be documented by Wellview Health and provided to a designated member of management.

iv. Management will utilize the test results to reach a determination regarding whether the employee will be permitted to return to the office that day and the following day.

v. Management decisions regarding an employee’s return-to-office will be made as follows: 1. If the test reflects the presence of an IgM marker, then the employee will not be allowed in the

office; employee will exit through the same door as he/she entered for the testing and return home to work remotely for 30 days; employee will be permitted to return for a new test after 30 days.

2. If the test reflects the presence of an IgG marker, then the employee will not be allowed in the office; employee will exit through the same door as he/she entered for the testing and return home to work remotely for 14 days; the employee will be permitted to return for a new test 14 days after test date.


3. If the test does not reflect the presence of IgG nor IgM, then the employee may proceed to his/her office and follow prescribed guidelines for in-office personnel as set forth in the various Protocols described herein.

Protocol 4: Ongoing Testing

The COVID-19 antibody testing described in Protocol 3 will be administered weekly during Phase 1 for employees who are voluntarily seeking to return to the office. As outlined in Protocol 3, Group A employees will receive testing at a scheduled time each Monday between 7:00am and 10:00am and Group B employees will receive testing each Wednesday between 7:00am and 10:00am. NOTE: This protocol is subject to change in the event tests become unavailable, a problem is identified with the test that is being used, or a better test becomes available.

Protocol 5: Data Capture/Reporting

As described and agreed-to by each employee on the requisite consent forms that must be completed before undergoing testing, Wellview Health will record test results and, in addition to providing results to a member of management present during testing for use in making an admission determination, will also send results to the Company CEO and COO by encrypted attachment by 5pm EDT on each testing day. Data captured for analysis and sharing will include:

• Randomly Selected ID # (assigned by Wellview) • Employee gender • Employee age • Employee temperature • Result of that day’s COVID-19 antibody testing

Protocol 6: Impact of a Positive Test on Group

During ongoing testing, if an employee, who was previously cleared to return to the office, tests positive for COVID-19 antibodies (IgM or IgG), then the employee will be directed to leave the building and return home in accordance with the criteria set forth in Protocol 3.iv. All other employees of that Group will be notified by call, email, and/or in-person conversation and similarly directed to return home and work remotely for 14 days, after which they will again be permitted to return to the office for COVID-19 antibody testing in accordance with Protocol 3. The employee that tested positive will be encouraged to use his or her best efforts to determine others with whom he or she had been in contact with during the 6 days prior to testing positive and to inform those contacts that they may have been exposed to the virus so that they can take appropriate measures. The employee will also be encouraged to contact the appropriate health department official(s) to participate in the State’s contact tracing program.

Protocol 7: Privacy and Health Information Security

Certain confidential health information will be collected regularly from at least some employees during the implementation of this Plan. The Company is committed to safeguarding employee health information and


maintaining employees’ right to privacy. We will seek to limit that information by having Wellview Health conduct the testing and maintain applicable information. Collected health information will include:

• Body temperature, collected by a non-contact digital thermometer; and • Serological (blood) test results to measuring COVID-19 antibodies, specifically IgM and IgG

Wellview Health clinicians will confidentially communicate collected health information only to the individual employee and to management (either the COO or CEO) for return-to-office decision-making purposes. Additional anonymized health information will be reported via encrypted email attachments and stored securely in an encrypted folder in our Sharepoint system. This data will be utilized for compiling and tracking information about the virus, as described herein. If you have concerns regarding the Company’s collection and utilization of this data, please raise those concerns with our CCO or CEO.

Protocol 8: General Building Sanitation

Restrooms, elevators, and entry doors fall under building management, but clearly are areas of higher risk as it relates to potential disease transmission. Employees should follow building guidelines for safe habits when entering the building, taking the elevator, and using restrooms. The building café and gym are closed until further notice. Touchless hand sanitizer stations have been added to key areas throughout the building and are also provided in our office reception area for use after transiting the building.

Protocol 9: Office Sanitation

Cleaning and Disinfecting 1. Prior to reopening the office, hands-free, pedestal-mounted hand sanitizer stations will be installed in the

following locations where employees unavoidably and repeatedly touch handles and keypads: • Next to the reception desk • In the employee lounges (although these are closed during Phase 1) • In the hallway behind the PIN-enabled glass doors • Next to the printers/copiers

2. Prior to reopening the office, we will engage a commercial cleaning company to disinfect offices following

CDC guidelines, using an electrostatic spray technique to ensure adhesion of the disinfectant to previously cleaned surfaces. Such cleanings will occur monthly during all Phases of this Plan.

3. Individual bottles of hand sanitizer will be provided at each employee workstation.

4. Disinfectant wipes will be provided in the reception areas, lounge areas, conference rooms, and printing areas of each office.

Protocol 10: Employee Expectations

Personal Protective Equipment


Company-provided masks will be worn in all common areas of the office (i.e. hallways, lounges, reception) but are not required in individual employee offices. Surgical gloves and other personal protective equipment (“PPE”) may be worn at employee discretion, but are not required. Responsible Choices Testing, signs, sanitation stations, and floor markings alone will not ensure a safe working environment. Employee decisions and behavior will determine the success of this Plan. To that end, employees are expected to use good judgment to determine whether they should, in fact, return to the office for work, given factors including possible exposure to the coronavirus at home or elsewhere; signs of sickness; and risk factors known only to the employee that increase the risk of a serious consequence if infected with the coronavirus. Social Distancing Employees will not meet in individual offices during Phase 1 and Phase 2 of this plan; face-to-face collaboration can be facilitated by scheduling the large conference rooms or by engaging other employees in areas that enable proper social distancing. Chivalrous behavior, such as holding the door for another employee, for now must be subordinated to responsible and respectful actions such as waiting until a fellow employee has passed through a door and is six feet or more away, before taking one’s own turn.

Protocol 11: Guidelines for In-Person Meeting amongst Employees

In line with CDC guidelines for social-distancing, in-person meetings will be limited to 4 employees in the Benevolence and Focus Conference Rooms and 3 employees in the Strive Conference Room. Seating in these conference rooms will be designated by signage to ensure 10 feet of separation between participants. No group meetings will be allowed in small conference rooms. Employees are encouraged to consider the use of outdoor spaces for in-person meetings and to limit the length of indoor meetings to 30 minutes.

Protocol 12: Guidelines for In-Person Meetings with Clients & Entrepreneurs

In-person client meetings are prohibited during Phase 1 of this plan but may be arranged in Phase 2 by mutual consent (following provision of informed-consent notification) with prior approval from management. Caution and care supersedes the convenience or desirability of in-person meetings, unless an in-person meeting can be conducted safely. When in-office client meetings are scheduled, the scheduling employee will meet his or her guest in the reception area and use a no-touch thermometer to establish that the guest’s temperature is below 99.9 degrees. Clients and employees will wear masks and avoid handshakes, hugs, etc. Client meetings will occur in one of the large conference rooms, per Protocol 11. Upon conclusion of the meeting, clients will be escorted out of the office through the reception area. At no time will a client be permitted past the PIN-enabled glass doors that separate the common area from employee offices. Employees are encouraged to consider the use of outdoor spaces for in-person meetings, as well. Whenever possible, meetings should be limited in length (i.e., 30 minutes).

Protocol 13: Guidelines for Activities in Common Areas of the Office

Common areas will display signage reminding employees of healthy hygiene practices (proper hand washing, use of face coverings, frequent disinfecting) and social distancing guidelines. In Phase 1, communal spaces will be closed. In later Phases, pub stool seating will be designated to ensure 10 feet of separation between


employees, and floor markings will compartmentalize the sink/beverage service area into 10-foot intervals and demarcate safe waiting distances on each side of the secured glass doors. Lounge-area padded seats will be rearranged to ensure 10 feet of distance between each seat. No more than 10 employees should be gathered in the communal spaces, and then only when observing safe distancing and while wearing face coverings.

Protocol 14: Knowledge Sharing

This plan will be updated or amended as appropriate based upon data and observations during actual implementation. From time to time, the management team may generate formal status updates or guidance to be disseminated to external partners and organizations, or publish articles and thought pieces intended for broadest circulation through media outlets. In general, updates or documents intended for external distribution should be reviewed by a minimum of the CEO and COO, and further reviewed by counsel.


Return to Office Plan PART 3: QUESTIONNAIRES


Questionnaire #1: Baseline

��

��

��

��

��

��

��

�� !��

��

��

� ��

��

�� !�

""# �$%&'"(&�")

"�� !�#��$��%��&'��&�%��#�!��"��&��#��(��"��&�� ))��

��*��"��(��!�!�� !��"��"�%��"��+�� !��!��%��

� ��,��-��"��%��&.�� &�� "��%��

��

!(&*#+�&!�,%)&�"))")

"�&��%��&�� /��"��"��0��#��"�&�� !��#��%��&�#��#��%%��#��

�� 1#��&��(�� "��!��&��0��1#�� &��%��!��%��&��

��%��%�� &��"�� "��2 �� "�%��

��"�� %��%��0�1�"�� "��0 �#�� &��

��"��#�� %��%��"&�%��&�%�� "��%��

� �� %��1��2 ��&��&��3��%��&�#�� &�� !��&

%��!��&�4��&��#�5656#��&��%��!��%��"��&�� &��

��"��7��!��%��#�%�� %��!��&��&��&��"��3��"��""��

��


8��% �� "��

5��2&%�� "�&��%��"��%��&��0��9 ��%��#��&��"��#��#��1��:�

;<��;#�;:��%��&�;#��;/�"��%��&�;��"��&��%%��%��

=��

>��8��

?��

7��

@��)� ��&

9��"��

A��%��B��

��

C ��

�� D��!

��

E��9��2&%

��!

��D��!

�9��!

�9�D��!

9��!

9�D��!

��!

��D��!

��.��F��

G�� H ��&�� I�0��@��H ��J�"��3��%�#�66@>>��>=6@1


K��A��&�� %�%��&��!�� I

�� "�&��!�� %�%�#�� %%�&L

�M�/%��

�M� ��

�M�)��&��

�M�)3��7��&

<��0�1

��

�6��A�!�&��!�� 0��

� �� %&1�� %��"��%��&��&��I

-�

D�

��A��&�� !��!��M�� I

��&�A�� M�7��

A��

?��

B��

��!��M�� 9��

��

�5��A�!�&��&� �� I

-�

D�

��.��F��


��

��

�=��C��&��"��!��"��&��I

-�

D�

�>��C��&��"��!��"��&��<��I�

-�

D�

�@��&��&��"�*��!��,I

-�

D�

�E��A��I

/��

�!��>��&��

�!��5K��&��

�� "��9��

��


�G��&��!�� &�� !��"��&�� %��I

-�

D�

�� "��<��

��

�K��C ��&��!�&��"��I

9"��56��

��56��

4��5656

7��5656

?��5656

�%��5656

?�&�5656

�� )3%��

��

��A�!�&��&�0�� >��1�� &�� %��!�"��

��I

-�

D�

��.��F��


56��&�� E�� !�&��!��%��"��!��* ��%��,I

-�

D�

��.��F��

7��"�)�%��&��

��

5�� &��%��&��%��%�� ""��0�1��%��"��I

-�

D�

��&��%�

��.��F��

D��%%��

7��9��""��<��%��2��

��

55��C ��&��%��&�M%��"��%��%��""��I

��&

C�� 5�C��

C�� >�C��

C�� E�C��

C�� K�C��


-��<��C��

��

5=��&��%��&��""��%��"��I

-�

D�

A�!�.��

D��%%��

-��<��C��2��

��

5>��C ��&��%��I

��&

C�� 5�C��

C�� >�C��

C�� E�C��

C�� K�C��

D��

5@�� &��!��&I

-�

D�


5E��C ��%��"�&��%��&I

�66N

K6N

E6N

>6N

56N

D��

5G��&��%��&� �!��<��""��I

-�

D�

��.��F��

5K��&��&%��&��%��3��&�0�� E�"�1�� I

-�

D�

5��C��&��M�$��!�I

-�

D�

/��)��!��/��

��

=6�� 3��K��#��&��%��M�� I

-�

D�

A�!�.��


�!�� D3��K�C��

��

=��&��&�% &��&��&�� %�"��"��I

-�

D�

=5��&��%��%��&�� 3��"��&I

-�

D�

==��&��%��!�&��%��&�� "��I

-�

D�

=>��&��%��%��&��%��&�� "��I

-�

D�

=@��&��%��%�� %��I

-�

D�

=E��&��%��I

-�

D�

=G��&��%�� %%��I

-�

D�


=K��&��%��!��&��I

-�

D�

=��&��%��!��"��!��I

-�

D�

>6��&��%��!��%��!��0�� &��1�� !��!�I

-�

D�

��!�?��-��!��2 �D3��K�C��

��

>��C�� %��)�� -��"��#��&��%��L

/��&�� %��

/��!�&�� %��

�� %��

>5��C�� %��)��'�� "��#��&��%��L

��

��

�� %��"��

>=��C��&�� &�� "�$��&�� I

-�

D�


>>��C��&��"��%��I

-�

D�

>@��C��&��"��%��I

-�

D�

>E��C��&�� "�� I

-�

D�

>G��C��&��0��&1��I

-�

D�

C��2��

��

>K�� "�&��%��&��%��!��0��&1�� &�� KNO

��&�� &��&��"��%�!��&��"�� !��!��#��&��

��I

-�

D�

��.��F��

��.��

��

��

�� !��

�� "��#��

��$��


��

>��C��&��%�&�P@6�"�� I

-�

D�

��.��

��

��

�� !��

�� "��#��

��$��

��

2 ��&��"��&��-�� %�� !��C��%%��&��

�� "�� $��

�� %��

��


Questionnaire #2: Symptoms To Evaluate an Employee Suspected of Having COVID-19

��

��

�� !��!"��

!��#��$�%��!��!�� !

��&��'��$�

��'��!��'��(��

!�� (��'��'��$�)��'��

��&��'��(�� !��

��''�'��(��!��$

�$�)�&�� '��*

��&�� '��'��!��$

��

�� !��(��+��(��!��(��"��!��,,��

��-��!��!��!��!"��#��

��$.��!��/��

��)�)$�

��

��!��0$'$(��(��(��(��(��$

��1(��!��!"��2��)��02)1(��2)�

��$�3��!��'��

��!��0�1�� !��0��(��'��

��(��&�� &��'��

��'�� &��1$�3��!��4��'�2)��(� ��

��!��5��(�6767(��!��

��$�8��2)��(��4��$

3��,��)��,��9��'��

��


��:;��(��4��<

6$�8��<

��

%�

=$�8��'�<

��

%�

:$��'�<

��

%�

>$��#��'<

��

%�

?$�)��@�2��<

��

%�

A$�B��%��<

��

%�

;$��3��<

��

%�

�$��<

��

%�


�7$��C��<

��

%�

��$�9��<

��

%�

�6$�3�� <

��

%�

�=$�D��B��<

��

%�

3��,��)��,��9��'��

��

�:$�9��!�� 4��!��E

��

%�

�>$�9��!�� E

��

%�

�?$�9��0�1��!��'��-��.E

��

%�


Return to Office Plan PART 4: APPENDIX


The forthcoming information reflects a good faith effort by management to provide useful, current information for employees’ interest and reference. We do not purport to be experts in this space and acknowledge that scientific understanding about the virus continues to evolve daily. This is provided for informational purposes only and should not be relied upon for any other purpose. This section will likely require updating, including additional clarification, as the COVID-19 pandemic continues to develop. This section was last updated May 13, 2020. What We Know GENERAL FACTS ABOUT CORONAVIRUSES

What are coronaviruses? Coronaviruses are a large family of viruses which may cause illness in animals or humans. They were first identified by scientists in the mid-1960s. Coronaviruses are named for the crown-like spikes on their surface. In humans, several coronaviruses are known to cause respiratory infections ranging from the common cold to more severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The most recently discovered coronavirus SARS-CoV-2 causes the coronavirus disease COVID-19. (Sources: WHO & CDC)

Are there different types of coronaviruses? Yes. There are four main groupings of coronaviruses known as alpha, beta, gamma and delta.

How many coronaviruses are there? Scientists have identified about 100 unique coronaviruses, most of which are carried by animals.

Do all these coronaviruses infect human beings?

No. Scientists believe that 7 of the ~100 identified coronaviruses have been transferred from animals to human beings. Common human coronaviruses (229E, NL63, OC43, and HKU1) frequently infect people around the world. Sometimes coronaviruses that infect animals can evolve and make people sick and become a new human coronavirus. Three recent examples include MERS-CoV, SARS-CoV, and SARS-CoV-2.

What are the 7 coronaviruses that infect human beings? Common human coronaviruses 1. 229E (alpha coronavirus) 2. NL63 (alpha coronavirus) 3. OC43 (beta coronavirus) 4. HKU1 (beta coronavirus)

Other human coronaviruses 5. MERS-CoV (the beta coronavirus that causes Middle East Respiratory Syndrome, or MERS) 6. SARS-CoV (the beta coronavirus that causes severe acute respiratory syndrome, or SARS) 7. SARS-CoV-2 (the novel coronavirus that causes the coronavirus disease 2019, or COVID-19).


FACTS ABOUT COVID-19

What is COVID-19?

COVID-19 is an abbreviation of COronaVirus Infectious Disease - 2019. COVID-19 is the infectious disease caused by the most recently discovered coronavirus, also known as the “novel coronavirus”. This new virus and disease were unknown before the outbreak began in Wuhan, China, in or about December 2019. COVID-19 is now a pandemic affecting many countries globally. (Source: WHO)

How is COVID-19 transmitted?

COVID-19 is believed to spread from person-to-person via respiratory droplets that are expelled (via speaking, coughing or sneezing) from someone who is infected. Respiratory droplets can travel from person-to-person via airborne droplets, surfaces droplets or potentially via liquids.

Airborne Risk

People who sneeze can expel respiratory droplets over a 10-foot distance (the radius) at an angel of about 30-45° forward or at lesser distances at an angle of 90° laterally or behind a coughing/sneezing person. Humans do not cough with as much force, but coughs can still expel respiratory droplets as far as 6 feet.

The CDC recommends social distancing of 6 feet and the WHO recommends social distancing of 3 feet. We prefer at least 10 feet of social distancing based on common sneezing distances.

This means that being in places like small rooms, elevators, cars, public transportation, airplanes and other confined spaces with an infected person increase the probability of becoming infected.

Surface Risk

Droplets can land on objects and surfaces around the person such as mobile phones, tablets, laptops, keyboards, tables, doorknobs, handrails and more. People can become infected by touching these objects or surfaces, then touching their eyes, nose or mouth. This is why it is important to thoroughly wash your hands regularly with soap and water for at least 20 seconds or clean with alcohol-based (60% or more) hand rub.

What is the infection cycle for COVID-19? And how do human bodies respond to COVID-19 infection?

Scientists believe that persons who are infected by the novel coronavirus are typically asymptomatic for around 5 days; however, newly emerging evidence suggests that an infected person can be asymptomatic for up to 14 days before showing symptoms. There are also cases where infected people show no symptoms from the disease but are nonetheless contagious. Scientist believe that most people who become infected do show symptoms and those symptoms range from mild to severe. The typical infection cycle is shown below.

After becoming infected with the novel coronavirus, most human beings begin to show symptoms. Their body begins to combat the disease with an antibody called IgM a few days after the onset of symptoms. As the infected person begins to recover, they begin to develop long-term antibodies presumably to defend the body against future attacks by the same virus. That antibody is called IgG and is typically measured to determine whether a person has been infected by a particular virus in the past and to assess whether a person may have a long-term immunity to a particular virus.

(Note: Some studies have concluded that the presence of IgG in a person’s bloodstream does not necessarily mean that a person is immune to the novel coronavirus. More study is required before any conclusions can be drawn.)


Source: http://www.diazyme.com/covid-19-antibody-tests

Can COVID-19 be caught from a person who has no symptoms?

Yes, even people with very mild to no symptoms of COVID-19 can transmit the virus. Infected people who exhibit no symptoms are referred to as asymptomatic.

What are the symptoms of COVID-19?

The most common symptoms of COVID-19 are fever, dry cough, and tiredness. Some patients may have aches and pains, nasal congestion, sore throat or diarrhea. The disease affects different people in different ways. Symptoms typically begin gradually. Some people become infected but only have very mild symptoms. Others experience a rapid onset of serious symptoms. Some people experience symptoms that worsen, improve and then worsen again.

For more information on COVID-19 symptoms, visit https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html

Does COVID-19 cause serious illness or even death?

According to the World Health Organization, most people (about 80%) recover from the disease without needing serious medical intervention (i.e., hospital treatment), meaning that around 1 out of every 5 people who gets COVID-19 becomes seriously ill. (Source: WHO).

Scientists, governments, and healthcare providers do not (and indeed, given the short period of time since the virus first emerged, cannot) have a full understanding of the percentage of the total global population that has been infected by the novel coronavirus. Evolving studies suggest that a greater percentage of the US population may have been infected by the virus than previously thought. If the total number of infected people is unknown and potentially off by orders of magnitude (i.e. the denominator is wrong) then it is not possible to reliably forecast the percentage of infected people who become seriously ill and require hospitalization. The estimate that 20% of infected people become require hospitalization may be overstated as there are very few countries in the world that have tested a statistically reliable portion of the population to identify people who were infected but were asymptomatic and/or had


only mild symptoms. (It is also likely that some people have died without having been tested and as such COVID-19 was not identified as a cause of death.)

What we can say with confidence is that the disease is highly contagious, causes serious illness or death in some of the people it infects, and that there is currently no vaccine, cure or treatment for COVID-19. As such, individuals should take all precautions to avoid becoming infected.

We are in agreement with those that feel that comprehensive testing (canvasing) of the US population is needed to better understand the percentage of previously and currently infected people before we can make predictions on hospitalization rates and case fatality rates. We simply do not have adequate data today and as a result must act with an abundance of caution.

Who is most at risk of serious illness or death if they catch COVID-19?

Current data suggests that older people, and those with underlying medical conditions like high blood pressure, heart and lung problems, diabetes, or cancer, are at higher risk of serious illness or death from COVID-19.

What should I do if I have COVID-19 symptoms?

Employees are expected to notify the company immediately at the onset of symptoms of any infectious disease. A critical element of our ability to implement a comprehensive risk management program is our ability to develop an early warning system and to gather information and take necessary actions. Employees are further expected to either (a) stay home (do not come to the office) if they are experiencing symptoms or (b) leave the office immediately at the onset of symptoms, being careful to respect our common area Protocols while departing.

When should I seek medical attention if I have symptoms of COVID-19?

The WHO advises that:

If you have minor symptoms

Such as a slight cough or a mild fever, there is generally no need to seek medical care. Stay at home, self-isolate and monitor your symptom.

If you have more severe symptoms

Such as a high fever or significant chest or nasal congestion which makes breathing difficult, then you should seek medical attention immediately.

If you plan to go to your physician’s office, then you should attempt to alert them in advance. When you visit a healthcare facility wear a mask if possible, keep at least 6 feet distance from other people and do not touch surfaces with your hands.

While the WHO guidance may be good for health systems that are trying to prevent being overrun, it is arguably not risk-minimizing, educational or comforting to individuals. You may want to call your primary care physician (PCP) at the earliest sign of symptoms. If your PCP is not available, remember that telemedicine calls are reimbursable under our health plan. If your symptoms become more severe, you will be better positioned to make a decision if you have already talked to a doctor.

We invite all employees to utilize the service provided by Wellview onsite weekly during all phases of this Plan and further encourage you to call your PCP at the earliest sign of symptoms or to address any questions or concerns that you might have regarding your health.


We are not qualified to provide you with medical or health care advice, and do not intend to provide any such advice above or herein.

COVID-19 RISK & MITIGATION FACTORS

What are the risk factors associated with the novel coronavirus?

Risk Factors are conditions, behaviors or other factors that are believed to increase a person’s chances of contracting a disease.

Conditions leading to increased risk of contracting the novel coronavirus:

• Being in the presence of another infected person

• Having an infected person in the same home

• Being in geographic “hot spots” where the virus is spreading or common

• Being around people who do not comply with social distancing guidelines

• Being in urban environments

• Being in confined and/or indoor spaces

• Working in close proximity to other human beings

• Being in an un-sanitized work environment

Behaviors leading to increased risk of contracting the novel coronavirus:

• Failing to be informed about your own infection status (see definition below)

• Failing to be informed about the infection status of your family and those people you spent time around

• Not complying with social distancing guidelines

• Failing to wash hands frequently or otherwise observe good hygiene practices

• Touching your face, especially while in the presence of other people

• Being in the presence of another infected person

• Drinking from the same glass or container as others

Who is at risk of becoming infected by the novel coronavirus?

People of all ages, genders and ethnicities can contract COVID-19

Who is most at risk of severe illness or death from COVID-19?

• Age appears to be a significant factor in predicting deaths and severity of illness.

• People with pre-existing chronic illnesses also appear to be more susceptible.

• Early studies have suggested that people with Blood Type A may be significantly more susceptible to the novel coronavirus (and people with Blood Type O may be significantly less susceptible) severe outcomes from COVID-19.

• There is no clear evidence today as to why some people in the same general cohorts are more impacted by the novel coronavirus than others. Studies are underway to understand why some people may be


more/less susceptible to the disease based on their genetics, pre-existing conditions, environments, past behaviors (including smoking, or having previously received vaccines or treatments for other viruses), etc.


Frequently Asked Questions How are we going to keep employees, clients, partners and vendors as safe as possible when we return to the office? We are implementing a comprehensive Return-to-Office Plan that is designed to significantly reduce the risk that our employees, clients, founders, and vendors contract coronavirus as a result of their interactions with our company. Is the Plan overkill? We don’t believe so. We recognize that other companies will publish off-the-shelf guidelines and some may do the bare minimum to protect employees and customers, but that is not our intention. We are risk managers, so we should have a comprehensive plan to manage the risks associated with returning to in-office work. Do I have to return to the office now? No. Your return to the office is entirely voluntary, until Phase 3 or thereafter. We encourage all employees to continue to work remotely whenever possible. Do all employees have to participate in the COVID-19 antibody testing program? No. Your participation in the testing program is entirely voluntary. However, if you do not participate in the testing program (for the safety of your colleagues and other members of our ecosystem), then you will be limited to working remotely until we determine that the risk of contracting and spreading the disease is significantly reduced. Do all employees have to answer the questionnaire? No. Your participation in the questionnaire is entirely voluntary. We are asking that you participate in the questionnaire so we can increase our understanding of factors that lead to the disease’s spread and impact on different people. Your participation, while not required, would be greatly appreciated.


About the Testing Protocols

Serological vs. PCR Testing

To the best of our knowledge, there are currently two main types of testing procedures for the novel coronavirus – Serological and PCR – both of which have shortcomings and advantages. As noted above, we have elected to contract with a healthcare service provider that will be utilizing serological testing. Serological tests measure the existence of antibodies, specifically IgM and IgG, in the blood.

Current understanding is that IgM spikes during early stages of coronavirus infections, shortly after the onset of symptoms. As the human body begins to develop a defense against the disease, IgM begins to diminish in the bloodstream and the IgG antibody increases.

Antibodies are measured in an effort to determine valuable pieces of information, such as:

i. If a person does not have a detectable quantity of either the IgM or IgG antibody in their bloodstream, then it is highly likely that they have not been infected with the novel coronavirus. (if they are very early in the infection process it is possible that the test may not detect the presence of antibodies in the bloodstream.)

ii. If a person has a high amount of IgM in their bloodstream, they are believed to be in the early stages of combating the illness.

iii. If a person has a high amount of IgG in their bloodstream, they are believed to either be in the later stages of fighting the virus or they may have already recovered from the disease, in which case they may have developed some immunity against future infections.

How Serological Testing Works

A serological test involves a procedure carried out on a sample of blood serum, the clear liquid that separates from the blood when it is allowed to clot. The procedure can take place in a lab or in a test kit apparatus. Typically, the laboratory test is more accurate than a portable test kit; however, the test kit is far easier to distribute and results are nearly immediate.

Canvasing vs. Select Targeting

Government officials have begun describing testing programs that involve select targeting (i.e., testing employees who exhibit symptoms that are common with the novel coronavirus). Our view is that this strategy is a step in the right direction, but it does not go far. Once a person exhibits symptoms, they are and have been highly contagious for at least several days. Moreover, the select targeting approach does not allow us to know who has IgG.


Limitations

We are in unchartered territory.

It’s entirely possible that parts of our return-to-office plan will not help us mitigate the spread of the novel coronavirus. This disease is highly infectious and our ability to control the disease within our office and ecosystem is dependent on many factors that are out of our control – like the behavior of other people who interact with our ecosystem.

We are focused on the areas that we can control, however, maintaining our commitment to the Plan may be difficult. Additionally, factors that could inhibit our ability to fully execute our plan effectively include, without limitation:

1. A much larger outbreak of COVID-19 than we are currently forecasting – thereby causing us to reassess;

2. A mutation in the virus that causes the Case Fatality Rate to rise – thereby causing us to reassess;

3. Testing failures (resulting from too many false positive and false negatives);

4. Individuals not sharing accurate information in the questionnaires;

5. Relaxing protocols as the number of cases nationally and in Georgia begin to fall;

6. Pressure shifting public or corporate policies; and

7. Complacency and fatigue that naturally tend to occur with the passage of time.

Other challenges involve the day-to-day of operation of our business. For instance, we may not be able to raise capital at the same pace virtually as when we are all in the office and are travelling to meet with potential investors in person. We will also have to work more intentionally and creatively to sustain the same culture without consistent in-person interaction.

Documents

Return to Office Plan - BIP Capital